- Research Article
- 10.1016/j.prro.2025.11.006
Standardization Versus Adaptability: Where Is the Sweet Spot?
- Feb 01, 2026
- Practical radiation oncology
- Mohammad Bakhtiari
Publications from 2021 to 2026
Showing 10 of 107 papers
Standardization Versus Adaptability: Where Is the Sweet Spot?
A call for responsible innovation in pediatric health care
Artificial intelligence (AI) is transforming healthcare by equipping clinicians and patients with tools that support more efficient, patient-centered care. In pediatrics, however, the implementation of AI demands a higher threshold for responsibility, transparency, and family-centered engagement. This perspective explores the opportunities and challenges of AI in pediatric healthcare, highlighting the unique ethical and developmental considerations that distinguish children’s care from adult medicine. Drawing on Kaiser Permanente’s seven principles for responsible AI, the article emphasizes the importance of augmentation over automation, the need for pediatric-specific validation, and the necessity of trustworthiness and fairness in clinical deployment. It outlines how AI can support primary care providers through enhanced decision support, early screening for developmental and behavioral disorders, including the potential for AI to create personalized developmental trajectories, moving beyond static population norms to provide earlier, more precise insights into a child’s neurodevelopmental progress, improved electronic health record usability, and risk prediction models. However, without careful governance, AI poses risks of bias, inequity, and erosion of clinician judgment. Policy recommendations include redesigning family consent models, ensuring robust clinician training, and mandating pediatric-specific testing of AI systems with diverse, representative datasets. Ultimately, AI should function as a supportive tool that strengthens, not replaces, human empathy, clinical expertise, and family-centered values. Responsible innovation is essential to ensure that children benefit equitably from AI while maintaining trust, safety, and compassion in pediatric healthcare.
Read moreRF020 INTERIM RESULTS FROM A GLOBAL MULTICENTER REGISTRY STUDY OF 10 KHZ SPINAL CORD STIMULATION FOR MANAGEMENT OF CHRONIC INTRACTABLE PAIN ASSOCIATED WITH DIABETIC NEUROPATHY
Metaplastic Breast Cancer Characteristics and Patterns of Recurrence: A Single Institution Experience.
Background Metaplastic breast cancer (MtBC) is a rare type of aggressive breast cancer. MtBChas multiple pathological subtypes, including squamous,sarcomatoid, spindle,adenosquamous, and mixed metaplastic. Given the rare nature of the disease, there is limited information available on the behaviour of this cancer and no well-defined recommendations for treatment. We aim to investigate the clinicopathological characteristics ofMtBC,including overall survival and patterns of recurrence. Methods We conducted asingle-institutionretrospective review of 91 patients with MtBC who presented from 2009 to 2024. We collected patient-specific, clinicopathological, and survival data. Recurrence-free interval, medical and surgical treatment, follow-up, and time to death were also collected.Dataisdescribed with frequency counts and percentages. Product-limit survival estimates were calculated from the time from diagnosis to last follow-up or death. Results Our population consisted of 91 patients; the mean age at diagnosis was 60 years. All patients were female; the majority were Caucasian (59, 67.1%), followed by African American (24, 27.3%). Sixty-six patients (72.5%)hada BMI >25,and 69 (78.4%) were postmenopausal. MtBCwasestrogen, progesterone, and humanepidermal growth factor(Her2)negative in 82 (90.1%), 88 (96.7%), and 80 (88.9%) of the patients, respectively. Forty-five patients(49.5%) underwent alumpectomy, 41 (45.1%) amastectomy, and one (1.1%) nosurgery. Sixty-four patients (73.6%) had undergone sentinel lymph node biopsy (SLNB), 16 (18.4%) hadaxillarylymph nodedissection (ALND), three (3.4%) had targeted axillarysurgery, and four (4.6%) had no axillary surgery. Sixty-six patients(76.7%) underwent chemotherapy,of which 27 (40.9%) were in theneoadjuvant chemotherapy (NACT) setting. Of the patients who underwent NACT, seven had a completepathological response. Twoof thepathologic complete response (pCR) groupreceived Keynote-522. In ourpopulation, 29 (36.3%)patients hada recurrence, of which 12 (41.4%) haddistant recurrence,with amedian time to recurrenceof12 months. The 12-month, 36-month, and 60-month overall survival rates were 93.9% (Standard Error (SE): 2.7%), 81.3% (SE: 4.8%), and79.2% (SE: 5.1%), respectively.There wasno significant difference inthe survivalrates (p= 0.88)or recurrencerates (p=0.19)for NACT versus adjuvantcases.Subgroupanalysis comparing patients with and without recurrence who received NACT revealed no statistically significant differences in clinicopathologic featuressuch as grade, ER, PR,HER2 status,or metaplastic subtype.Moreover, 20 patientsinthis study received both chemotherapy and immunotherapy,and six (33.3%) experienced recurrences, withno significant differences in recurrence rates,recurrence pattern (p=0.40),or timing (p=0.32) between NACT and adjuvant groups. Conclusion We demonstratedthatMtBCexhibits aggressive oncologic behaviour, often with triple-negative receptor status and high Ki-67. The most common pattern ofrecurrenceis distant, mainly involving the lungs; hence, a chest tomography was essential during the one-year follow-up to detect these lesions. Seven patients (25.9%) whoreceivedNACT achieveda pCR,indicatingthatNACT can be highly beneficial for a subset of patients.Further studies investigating the effects ofNACT, especially keynote-522, in a larger population are necessary tocreate standardized treatment.
Read moreSerum Exosomes from a Uniquely Defined Early-Adult Donor Cohort Reprogram Endothelial Transcriptomes Linked to Alzheimer’s Pathogenesis
Abstract Age-related changes in circulating exosomes are implicated in cerebrovascular aging and the pathogenesis of Alzheimer’s disease (AD). Neurovascular dysfunction and blood-brain barrier (BBB) breakdown are recognized as early events in AD, often preceding amyloid-β deposition. Primary human brain micro endothelial cells (HBMECs) from a 38-year-old male were treated with exosomes from young (18–25 years) and old (65–72 years) donors. Whole transcriptomic RNA sequencing analysis identified 5,432 differentially expressed genes, which were organized into five transcriptional clusters. Two principal clusters demonstrated reciprocal patterns: 1) exosomes derived from serum of older adult donors (65–72 years) downregulated genes essential for mitochondrial function (e.g., oxidative phosphorylation) and protein synthesis (e.g., ribosomal biogenesis) and 2) upregulating genes linked to inflammation, junctional remodeling, and proliferative signaling. Crucially, subsequent treatment with exosomes derived from serum of young adult donors (18–25 years) reversed these detrimental transcriptomic profiles via restoration of the expression of mitochondrial and ribosomal machinery toward baseline and suppressed the inflammatory and maladaptive proliferative signaling induced by exosomes derived from serum of older adult donors. These findings demonstrate that exosomes derived from serum of young adult donors can counteract detrimental signals of aging at the transcriptional level, reinforcing the cellular architecture underlying BBB integrity. This supports the therapeutic potential of using exosomes derived from serum of young adult donors to reverse endothelial aging and interrupt the early neurovascular dysfunction that contributes to the progression of AD.
Read moreHuman evaluation of large language models in healthcare: gaps, challenges, and the need for standardization
Publications related to experimentation with Large Language Models (LLMs) in healthcare are rapidly increasing. While human evaluation remains the gold standard for evaluating LLMs, there is still a lack of standardization in its implementation. In this review article, we systematically examine studies involving LLMs in healthcare that have conducted human evaluations. We analyze the metrics used, assess their variability across studies. We also propose a standardized framework along with an interactive open web application HumanELY, to facilitate human evaluation. We believe that use of HumanELY will provide an opportunity for consistent, comprehensive, reliable, reproducible, and measurable human evaluations of LLM in healthcare. HumanELY is publicly available at https://www.brainxai.com/humanely .
Read moreAbstract 233: Collateral Status and Outcomes in ICAS‐LVO: Insights From the RESCUE‐ICAS Registry
Introduction The influence of collateral circulation on outcomes in intracranial atherosclerotic stenosis‐related large vessel occlusion (ICAS‐LVO) treated with mechanical thrombectomy (MT) with or without rescue stenting is not well defined. We aimed to determine whether collateral status modifies the effect of stenting on angiographic and clinical outcomes. Methods We analyzed patients with ICAS‐LVO in the RESCUE‐ICAS registry who underwent MT alone or with rescue stenting in the anterior circulation. Collaterals were graded as good or bad based on ASITN/SIR score. Outcomes included functional independence (mRS 0‐2 at 90 days), mortality, successful recanalization, sICH, and 24‐hour DWI infarct volume. Regression models evaluated stenting and collateral status interaction, adjusted using inverse probability weighting for age, sex, race, diabetes, hypertension, atrial fibrillation, hyperlipidemia, prior stroke, smoking, pre‐stroke mRS, admission NIHSS, IV tPA, and baseline ASPECTS, with weights trimmed at ≤4. Results A total of 324 patients were included (MT alone, n=182; stent+MT, n=142). Median age was 67 years, 57% were male, and vascular comorbidities were frequent. Good collaterals were present in 27% of cases. Interaction analysis between stenting and collateral status showed no significant effect modification for functional independence (adjusted OR 0.78, 95% CI 0.33‐1.82, p =0.560), mortality (adjusted OR 1.56, 95% CI 0.52‐4.68, p =0.425), sICH (adjusted OR 0.22, 95% CI 0.04‐1.42, p =0.112), or infarct volume (β = ‐10.1 mL, 95% CI ‐32.9 to 12.7, p =0.656). A borderline interaction was observed for successful recanalization, with stenting in the setting of good collaterals associated with higher odds of reperfusion (adjusted OR 5.34, 95% CI 0.90‐31.7, p =0.065). Conclusions In patients with anterior circulation ICAS‐LVO, collateral status did not significantly modify the benefit of rescue stenting. These findings suggest that good collaterals alone do not obviate the need for stenting, and highlight the need for prospective studies to define optimal medical management strategies in this population. image image
Read moreSodium-glucose cotransporter 2 inhibitor in heart failure patients and their outcomes: A meta-analysis of randomized controlled trials
BACKGROUNDThe use of sodium-glucose cotransporter 2 (SGLT2) inhibitor in heart failure (HF) patients is increasing significantly, regardless of whether they have a history of diabetes. The effects of SGLT2 inhibitor on HF are likely mediated through multiple mechanisms, including suppression of the renin-angiotensin-aldosterone system (RAAS), reduction in oxidative stress leading to enhanced myocardial efficiency, and attenuation of adverse cardiac remodeling by preventing fibrosis. These pathways are fundamental to reducing mortality, improving patients' quality of life, and alleviating the burden on the United States healthcare system by decreasing HF-related hospitalizations.AIMTo evaluate SGLT2 inhibitor effects on HF, focusing on hospitalization for HF (HHF), cardiovascular (CV) deaths, and all-cause mortality.METHODSA comprehensive search was conducted in PubMed for randomized controlled trials (RCTs) evaluating the effects of SGLT2 inhibitor in HF patients compared to placebo, covering the period from January 1, 2014, to January 1, 2025. The primary outcomes assessed were HHF, CV deaths, and all-cause mortality. RevMan Web 5.4.1 was used to assess the risk of bias heterogeneity and to perform the statistical analyses. A random-effects model was employed for all statistical evaluations.RESULTSA total of nine RCTs were included in this analysis: DELIVER, DECLARE-TIMI 58, DAPA-HF, EMPA-REG OUTCOME, EMPEROR-Reduced, EMPEROR-Preserved, SOLOIST-WHF, EMPULSE, and VERTIS-CV. For HHF, eight trials (excluding the SOLOIST-WHF; n = 25906) were pooled, while CV deaths were assessed using data from eight trials (excluding the EMPULSE; n = 26598). Compared to placebo, SGLT2 inhibitor significantly reduced the risk of HHF (relative risk: 0.74; 95%CI: 0.71-0.77; P < 0.00001) and CV death (odds ratio: 0.88; 95%CI: 0.83-0.92; P = 0.0006). All nine trials (n = 27128) were included in the analysis of all-cause mortality. SGLT2 inhibitor were associated with a statistically significant reduction in all-cause mortality compared to placebo (OR: 0.91; 95%CI: 0.84-0.98; P = 0.02).CONCLUSIONThese results suggest that SGLT2 inhibitor significantly reduce the risk of hospitalization for HF, CV deaths, and all-cause mortality.
Read moreAI as a Novel Digital Stressor in Adolescent Psychosis: Clinical and Ethical Implications.
ObjectiveWith the rapid adoption of artificial intelligence (AI) technologies by adolescents, the impact on their mental health is of critical concern. This article examines the emerging phenomenon of AI-related psychosis, which can be defined as new-onset or exacerbated psychotic experiences with generative AI platforms, such as chatbots, avatars, and virtual agents like Siri and Alexa.MethodNarrative review and perspective.ResultsAdolescents are particularly susceptible due to ongoing neurodevelopmental immaturity, including underdeveloped prefrontal regulatory circuits and heightened limbic system reactivity, which may impair emotional regulation and reality testing. Combined with extensive digital engagement, these factors increase vulnerability to psychotic experiences in response to AI interactions. This article examines behavioral risk factors, online habits, and neurobiological susceptibilities that may predispose adolescents to such experiences. In addition, implications are outlined for healthcare providers, including an emphasis on proactive screening, digital literacy education, and early intervention strategies. Clinical approaches to recognize and manage AI-related mental health risks in adolescents are also proposed.ConclusionsA multidisciplinary response by clinicians, educators, developers, and policymakers is needed to guide ethical AI design and safeguard the well-being of adolescents in today's digital environment.
Read moreEvaluation of workload among Board-Certified Psychiatric Pharmacists in the United States
IntroductionBoard-Certified Psychiatric Pharmacists (BCPPs) are highly trained mental health providers. The workload of clinical pharmacists has been inconsistently reported in the literature. The goals of this study were to quantify the typical and ideal workloads of BCPPs and characterize their practice settings and clinical activities.MethodsThis was a cross-sectional survey study of BCPP members of the American Association of Psychiatric Pharmacists. The survey included demographic, practice-related, and burnout questions. The primary outcome was the self-reported typical and ideal workloads of BCPPs in inpatient, outpatient, and transition-of-care settings. Secondary outcomes included practice settings and types of activities.ResultsOf 571 invitees, 173 respondents were included in the analysis. The mean typical number of patients per day for inpatient and outpatient BCPPs were 35.6 (±22.8) and 9.29 (±10.9), respectively. The mean ideal number of patients per day for inpatient and outpatient BCPPs were 23.6 (±10.4) and 9.96 (±10.6), respectively. Inpatient pharmacists reported spending 15.4 (±12.2) hours on direct patient care and consults during a typical workweek compared with outpatient pharmacists (25.4 ± 15.1, p ≤ .001). A greater number of outpatient pharmacists reported that electronic health record documentation contributed to a significant portion of their workflow compared with inpatient pharmacists (96.2% versus 71.9%, respectively, p ≤ .001).DiscussionThis was the first study to quantify BCPPs self-reported typical and ideal workload in different practice settings. Future research is needed to identify the factors that determine ideal workloads for BCPPs at specific practice sites.
Read more